Long-Term Use of Different Doses of Low-Molecular-Weight Heparin Versus Vitamin K Antagonists in the Treatment of Venous Thromboembolism

Romera-Villegas, Antonio; Cairols-Castellote, M.A.; Vila-Coll, R.; Martí-Mestre, Xavier; Colomé, E.; Iguaz, I.

doi:10.1016/j.avsg.2009.08.006

Cited by 27 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the subacute or chronic treatment periods, when the risk of VTE recurrence is not as high, published data provide weak support for LMWH dose reduction in patients with thrombocytopenia (< 50 × 10 9 L −1 ) . Platelet transfusion is probably not warranted.…”

Section: Management Of Cat In Patients With Thrombocytopeniamentioning

confidence: 99%

Management of challenging cases of patients with cancer‐associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH

Carrier

Khorana

Zwicker

et al. 2013

Journal of Thrombosis and Haemostasis

163

111

View full text Add to dashboard Cite

Section: Management Of Cat In Patients With Thrombocytopeniamentioning

confidence: 99%

Management of challenging cases of patients with cancer‐associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH

Carrier

Khorana

Zwicker

et al. 2013

Journal of Thrombosis and Haemostasis

163

111

View full text Add to dashboard Cite

“…The literature data suggests that the treatment with LMWH is associated with less episodes of VTE recurrence, pulmonary embolism, deaths with concomitant lower risk of complications and with better recanalisation rate of thrombosed deep vein segments and preservation of valvular function [15,20,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the deep vein recanalisation and function after low molecular weight heparin (calcium nadroparine) therapy of deep vein thrombosis. Preliminary report

Kaźmierski

2016

Acta Angiologica

View full text Add to dashboard Cite

show abstract

“…In any case, individual risks for recurrent VTE and bleeding should be assessed on a regular basis and be carefully weighed against each other. Since only case reports and small prospective cohort studies are available, recommendations are based on expert opinions rather than on robust evidence [64][65][66]. Nevertheless, there is increasing empirical knowledge regarding the management of thrombocytopenic cancer patients with dose-adjusted LMWH [67].…”

Section: How Should Anticoagulation Be Managed During Phases Of Thrommentioning

confidence: 99%

Management of cancer-associated venous thromboembolism – a case-based practical approach

Voigtlaender

2018

Vasa

View full text Add to dashboard Cite

Summary:In patients with solid tumours or haematological malignancies, venous thromboembolism (VTE) is a leading cause of death and signifi cantly contributes to morbidity and healthcare resource utilization. Current practice guidelines recommend long-term anticoagulation with low-molecular-weight heparin (LMWH) as the treatment of choice for cancer-associated VTE, based on clinical trial data showing an overall improved safety and effi cacy profi le of LMWH compared to vitamin K antagonists.However, several open questions remain, e. g. with regard to the intensity and duration of LMWH therapy; moreover, recent realworld evidence indicates that adherence to parenteral anticoagulation with LMWH over the course of treatment is poor in clinical practice. In this regard, the direct oral factor Xa or thrombin inhibitors (DOACs) have emerged as potential alternatives in the management of patients with cancer-associated VTE, albeit fi ndings from randomized controlled studies with a direct head-tohead comparison of DOACs with LMWH, the current standard of care, are still lacking. Based on the case of a lymphoma patient experiencing symptomatic pulmonary embolism during immunochemotherapy, this article aims at both highlighting the current state-of-the-art approach to cancer-associated VTE and pointing out some of the unresolved, controversial issues clinicians have to face when taking care of haematology and oncology patients with already established or with high risk of developing VTE. These issues include the management of patients with incidental pulmonary embolism or thrombocytopenia, the use of DOACs, and the initiation of pharmacological thromboprophylaxis in non-surgical cancer patients.

show abstract

Long-Term Use of Different Doses of Low-Molecular-Weight Heparin Versus Vitamin K Antagonists in the Treatment of Venous Thromboembolism

Cited by 27 publications

References 25 publications

Management of challenging cases of patients with cancer‐associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH

Management of challenging cases of patients with cancer‐associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH

Evaluation of the deep vein recanalisation and function after low molecular weight heparin (calcium nadroparine) therapy of deep vein thrombosis. Preliminary report

Management of cancer-associated venous thromboembolism – a case-based practical approach

Contact Info

Product

Resources

About